A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 2196
- Registration Number
- NCT06052267
- Locations
- 🇧🇬
Teva Investigational Site 59222, Plovdiv, Bulgaria
🇵🇱Teva Investigational Site 53524, Gdansk, Poland
🇵🇱Teva Investigational Site 53538, Gdansk, Poland
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia
- Conditions
- Schizophrenia
- Interventions
- Drug: TV-44749 - Dose level 3Drug: TV-44749 - Dose level 1Drug: PlaceboDrug: TV-44749 - Dose level 2
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 675
- Registration Number
- NCT05693935
- Locations
- 🇺🇸
Teva Investigational Site 15460, Bentonville, Arkansas, United States
🇺🇸Teva Investigational Site 15465, Little Rock, Arkansas, United States
🇺🇸Teva Investigational Site 15453, Rogers, Arkansas, United States
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
- Conditions
- Colitis, UlcerativeCrohn Disease
- Interventions
- Drug: TEV-48574 Dose Regimen ADrug: TEV-48574 Dose Regiment B
- First Posted Date
- 2022-12-29
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT05668013
- Locations
- 🇵🇱
Teva Investigational Site 53518, Nowy Targ, Poland
🇵🇱Teva Investigational Site 53516, Poznan, Poland
🇵🇱Teva Investigational Site 53566, Poznan, Poland
A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 290
- Registration Number
- NCT05499130
- Locations
- 🇧🇬
Teva Investigational Site 59197, Sofia, Bulgaria
🇧🇬Teva Investigational Site 59199, Sofia, Bulgaria
🇧🇬Teva Investigational Site 59196, Sofia, Bulgaria
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT05458011
- Locations
- 🇨🇳
Teva Investigational Site 88022, Changsha Shi, China
🇨🇳Teva Investigational Site 88015, Suzhou Shi, China
🇨🇳Teva Investigational Site 88023, Tianjin Shi, China
A Study to Test if TEV-53275 is Effective in Relieving Asthma
- Conditions
- Asthma
- Interventions
- Drug: TEV-53275 Dose ADrug: TEV-53275 Dose BDrug: Placebo
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04847674
- Locations
- 🇺🇸
Teva Investigational Site 15143, Los Angeles, California, United States
🇺🇸Teva Investigational Site 15185, Pittsburgh, Pennsylvania, United States
🇺🇸Teva Investigational Site 15188, Hoover, Alabama, United States
A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT04682353
- Locations
- 🇺🇸
Teva Investigational Site 14002, Cypress, California, United States
🇺🇸Teva Investigational Site 14003, San Antonio, Texas, United States
🇩🇴Teva Investigational Site 18001, Santo Domingo, Dominican Republic
A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
- Conditions
- Asthma
- Interventions
- Drug: Standard of Care Asthma MedicationDrug: Standard of Care Rescue Medication
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 427
- Registration Number
- NCT04677959
- Locations
- 🇺🇸
Teva Investigational Site 14974, Fountain Valley, California, United States
🇺🇸Teva Investigational Site 14982, Los Angeles, California, United States
🇺🇸Teva Investigational Site 14955, Fort Lauderdale, Florida, United States
A Study to Test if TEV-48574 is Effective in Relieving Asthma
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04545385
- Locations
- 🇺🇸
Teva Investigational Site 14896, Los Angeles, California, United States
🇺🇸Teva Investigational Site 14918, Los Angeles, California, United States
🇺🇸Teva Investigational Site 14921, Houston, Texas, United States
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 476
- Registration Number
- NCT04530110
- Locations
- 🇮🇹
Teva Investigational Site 30230, Firenze, Italy
🇮🇹Teva Investigational Site 30239, Milano, Italy
🇮🇹Teva Investigational Site 30228, Milano, Italy